# A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

> **NCT03025698** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Aplastic Anemia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** hATG
- **DRUG:** CsA

## Key facts

- **NCT ID:** NCT03025698
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-30
- **Primary completion:** 2022-04-22
- **Final completion:** 2025-01-27
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03025698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03025698, "A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03025698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*